TY - JOUR
T1 - Folate intake, MTHFR polymorphisms, and the risk of colorectal cancer
T2 - A systematic review and meta-analysis
AU - Kennedy, Deborah A.
AU - Stern, Seth J.
AU - Matok, Ilan
AU - Moretti, Myla E.
AU - Sarkar, Moumita
AU - Adams-Webber, Thomasin
AU - Koren, Gideon
PY - 2012
Y1 - 2012
N2 - Background. The objective was to determine whether relationships exist between the methylene-tetrahydrofolate reductase (MTHFR) polymorphisms and risk of colorectal cancer (CRC) and examine whether the risk is modified by level of folate intake. Methods. MEDLINE, Embase, and SCOPUS were searched to May 2012 using the terms folic acid, folate, colorectal cancer, methylenetetrahydrofolate reductase, MTHFR. Observational studies were included which (1) assessed the risk of CRC for each polymorphism and/or (2) had defined levels of folate intake for each polymorphism and assessed the risk of CRC. Results. From 910 references, 67 studies met our criteria; hand searching yielded 10 studies. The summary risk estimate comparing the 677CT versus CC genotype was 1.02 (95 CI 0.951.10) and for 677TT versus CC was 0.88 (95 CI 0.800.96) both with heterogeneity. The summary risk estimates for A1298C polymorphisms suggested no reduced risk. The summary risk estimate for high versus low total folate for the 677CC genotype was 0.70 (95 CI 0.560.89) and the 677TT genotype 0.63 (95 CI 0.410.97). Conclusion. These results suggest that the 677TT genotype is associated with a reduced risk of developing CRC, under conditions of high total folate intake, and this associated risk remains reduced for both MTHFR 677 CC and TT genotypes.
AB - Background. The objective was to determine whether relationships exist between the methylene-tetrahydrofolate reductase (MTHFR) polymorphisms and risk of colorectal cancer (CRC) and examine whether the risk is modified by level of folate intake. Methods. MEDLINE, Embase, and SCOPUS were searched to May 2012 using the terms folic acid, folate, colorectal cancer, methylenetetrahydrofolate reductase, MTHFR. Observational studies were included which (1) assessed the risk of CRC for each polymorphism and/or (2) had defined levels of folate intake for each polymorphism and assessed the risk of CRC. Results. From 910 references, 67 studies met our criteria; hand searching yielded 10 studies. The summary risk estimate comparing the 677CT versus CC genotype was 1.02 (95 CI 0.951.10) and for 677TT versus CC was 0.88 (95 CI 0.800.96) both with heterogeneity. The summary risk estimates for A1298C polymorphisms suggested no reduced risk. The summary risk estimate for high versus low total folate for the 677CC genotype was 0.70 (95 CI 0.560.89) and the 677TT genotype 0.63 (95 CI 0.410.97). Conclusion. These results suggest that the 677TT genotype is associated with a reduced risk of developing CRC, under conditions of high total folate intake, and this associated risk remains reduced for both MTHFR 677 CC and TT genotypes.
UR - http://www.scopus.com/inward/record.url?scp=84869054092&partnerID=8YFLogxK
U2 - 10.1155/2012/952508
DO - 10.1155/2012/952508
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:84869054092
SN - 1687-8558
JO - Journal of Cancer Epidemiology
JF - Journal of Cancer Epidemiology
M1 - 952508
ER -
